FUNDAMENTALS · Fundamentals · US Healthcare

Nexalin Technology (NXL) Fundamentals 2026 — Revenue Analysis | SniperIQ

Nexalin Technology (NXL) is a US-listed Healthcare company in Medical - Devices with a market capitalization of

0M, trading at $0.46 on the NASDAQ. This SniperIQ fundamentals page covers Nexalin Technology's valuation, profitability (net margin -3022.9%), revenue (
01,647 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
0M
Net Margin-3022.9%
Revenue (FY25)
01,647

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Nexalin Technology's market cap?

Nexalin Technology (NXL) has a market capitalization of approximately

0M, trading at $0.46 on the NASDAQ. Market cap moves with the live share price.

What is Nexalin Technology's P/E ratio?

Nexalin Technology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Nexalin Technology?

Nexalin Technology runs a net profit margin of -3022.9%, a gross margin of -102.9%, and an operating margin of -3084.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Nexalin Technology generate?

Nexalin Technology reported revenue of

01,647 for fiscal year 2025, with net income of -$8M and earnings per share (EPS) of -0.5. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Nexalin Technology pay a dividend?

Nexalin Technology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Nexalin Technology financially healthy?

Nexalin Technology carries a debt-to-equity ratio of 0.00x and a current ratio of 4.07x, with a market beta of 4.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Nexalin Technology a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nexalin Technology (NXL) the key facts are: market cap

0M, revenue
01,647, 52-week range 0.305-2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Nexalin Technology's full fundamentals live

Get Nexalin Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Cuprina Holdings (Cayman) (CUPR) fundamentals · BioVie (BIVI) fundamentals · OSR Holdings (OSRH) fundamentals · Burning Rock Biotech (BNR) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons